Compounds > bicalutamide

bicalutamide and mdv 3100

bicalutamide has been researched along with mdv 3100 in 65 studies

Research

Studies (65)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (1.54)29.6817
2010's46 (70.77)24.3611
2020's18 (27.69)2.80

Authors

AuthorsStudies
Chen, C; Jung, ME; Ouk, S; Sawyers, CL; Tran, C; Wongvipat, J; Yoo, D1
Axerio-Cilies, P; Ban, F; Cherkasov, A; Frewin, K; Hassona, MD; Labriere, C; Lack, NA; Leblanc, E; Li, H; Munuganti, RS; Rennie, PS; Singh, K; Tomlinson Guns, E; Young, R1
Ates-Alagoz, Z; Gediya, LK; Godbole, AM; Kwegyir-Afful, AK; Martin, MS; Njar, VC; Purushottamachar, P; Ramalingam, S; Vasaitis, TS1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Akbashev, MJ; Dillard, P; Gryder, BE; Khan, S; Meyers, WM; Oyelere, AK; Raftery, ED; Rood, MK1
Kwegyir-Afful, AK; Martin, MS; Mbatia, HW; Njar, VC; Ramalingam, S; Ramamurthy, VP1
Chufarova, NV; Ivachtchenko, AV; Ivanenkov, YA; Karapetian, RN; Koryakova, AG; Kravchenko, DV; Kuznetsova, IV; Mitkin, OD; Shevkun, NA; Trifelenkov, AS; Veselov, MS; Vorobiev, AA1
Kandil, S; McGuigan, C; Westwell, AD1
Bassetto, M; Brancale, A; Ferla, S; Kandil, S; McGuigan, C; Pertusati, F; Westwell, AD2
Cen, S; He, Y; Hu, L; Li, Q; Li, X; Liu, Y; Wu, M; Zhou, J1
Ban, F; Cherkasov, A; Dalal, K; Fernandez, M; Lack, N; LeBlanc, E; Li, H; Morin, H; Prinz, H; Rennie, PS; Shepherd, A; Tam, KJ1
Bassetto, M; Brancale, A; Ferla, S; Khandil, S; McGuigan, C; Pertusati, F; Westwell, AD1
Kandil, SB; Kariuki, BM; McGuigan, C; Westwell, AD1
He, Y; Hwang, DJ; Miller, DD; Mohler, ML; Narayanan, R; Ponnusamy, S; Thiyagarajan, T1
Ban, F; Cavga, AD; Chang, MEK; Chen, G; Cherkasov, A; Flory, MR; Ghaidi, F; Gleave, ME; Huang, CF; Lack, NA; Lallous, N; Lawn, S; Leblanc, E; Lingadahalli, S; Mohammed, H; Mohan, S; Morin, H; Rennie, PS; Young, RN; Yu, IPL1
Wang, S; Xiang, W1
Arora, V; Beer, TM; Chen, CD; Chen, Y; Clegg, NJ; Higano, CS; Hung, DT; Jung, ME; Kwon, A; Ouk, S; Sawyers, CL; Scher, HI; Smith-Jones, PM; Tran, C; Wasielewska, T; Watson, PA; Welsbie, D; Wongvipat, J; Yoo, D1
Aparicio, A; Arora, V; Bischoff, ED; Bonnefous, C; Cai, L; Cao, C; Chen, Y; Clegg, NJ; Darimont, B; De Stanchina, E; Dilhas, A; Dorow, S; Grillot, K; Hager, JH; Herbert, MR; Heyman, RA; Joseph, JD; Jung, ME; Klang, M; Ouerfelli, O; Ouk, S; Qian, J; Rix, PJ; Sawyers, CL; Scher, HI; Sensintaffar, J; Shao, G; Smith, ND; Smith-Jones, P; Tran, C; Wasielewska, T; Wongvipat, J; Wu, N; Yang, G; Zhao, H1
Arlt, W; Attard, G; Carreira, S; de Bono, JS; Goodall, J; Hay, CW; Lim, AC; McEwan, IJ; Nowakowska, K; Pezaro, C; Richards, J; Taylor, AE; Wingate, A1
Belikov, S; Jääskeläinen, T; Öberg, C; Palvimo, JJ; Rahkama, V; Wrange, Ö1
Beer, TM; Drake, CG; Graff, JN1
Chang, C; Fujimoto, N; Lee, SO; Li, L; Liang, L; Lin, TH; Niu, Y; Xu, D; Yeh, S; Yeh, SD1
Ha, YS; Jung, YS; Kim, IY; Kim, JH; Kim, WJ; Lee, GT1
Chang, C; Izumi, K; Lee, SO; Lin, TH; Lin, WJ; Yeh, S1
D'Agostino, R; Flores, A; Hassan, S; Karpova, Y; Kulik, G1
Alfaro, IE; Bernales, S; Cittelly, DM; Cochrane, DR; D'Amato, NC; Edgerton, SM; Elias, AD; Gómez, F; Guerrero, J; Howe, EN; Jacobsen, BM; Jean, A; Jedlicka, P; McCullagh, E; Medicherla, S; Protter, AA; Richer, JK; Spoelstra, NS; Thor, AD; Torkko, KC1
Honkakoski, P; Huhtala, T; Jääskeläinen, T; Juvonen, RO; Kaikkonen, S; Küblbeck, J; Laatikainen, R; Närvänen, A; Palvimo, JJ; Peräkylä, M; Petsalo, A; Poutiainen, PK; Pulkkinen, JT; Raunio, H1
Culig, Z1
Dagvadorj, A; Ellsworth, E; Gu, L; Gupta, S; Hoang, DT; Koptyra, M; Leiby, B; Liao, Z; Merry, DE; Mirtti, T; Montie, H; Nevalainen, MT; Savolainen, S; Shen, F; Talati, PG; Tan, SH1
Dobi, A; Li, H; McLeod, DG; Mohamed, AA; Petrovics, G; Sesterhenn, IA; Sharad, S; Song, Y; Sreenath, T; Srivastava, S; Umeda, E; Young, D1
Chang, C; Dang, Q; He, D; Li, L; Liang, L; Song, W; Xie, H; Yang, Z; Yeh, S1
Armstrong, C; Gao, AC; Liu, C; Lou, W; Sandher, A; Zhu, Y1
Cork, D; Davies, BR; Gaughan, L; Grey, J; Guo, W; Jones, D; Nakjang, S; O'Neill, D; Robson, CN; Wade, M; Wedge, SR1
Chaytor, L; Gaughan, L; Grey, J; Jones, D; Nakjang, S; Robson, CN; Wade, M1
Bhattacharya, S; Chowdhury, S; Hasabou, N; Heidenreich, A; Klotz, L; Shore, ND; Siemens, DR; van Os, S; Villers, A; Wang, F1
Agarwal, N; Armstrong, AJ; Concepcion, R; Dunshee, C; Higano, CS; Karsh, L; Krivoshik, A; Olsson, C; Penson, DF; Phung, D; Wang, F; Wu, K1
Awrey, S; Azad, AA; Cherkasov, A; Chi, KN; Collins, CC; Gleave, ME; Lallous, N; LeBihan, S; Leblanc, E; Murillo, J; Rennie, PS; Singh, K; Tse, R; Volik, SV; Wyatt, AW1
Chang, C; Li, L; Niu, Y; Tian, J; Wen, S; Yeh, S1
Bogner, J; Hickson, I; Romer, T; Yurlova, L; Zolghadr, K1
El-Shishtawy, KA; Ide, H; Kashiwagi, E; Kawahara, T; Li, Y; Miyamoto, H; Reis, LO; Zheng, Y1
Akbor, M; Culig, Z; Handle, F; Heidegger, I; Hoefer, J; Klocker, H; Ofer, P; Parson, W; Puhr, M1
Baron, B; Chowdhury, S; Heidenreich, A; Holmstrom, S; Ivanescu, C; Klotz, L; Lin, P; Shore, ND; Siemens, DR; Villers, A; Wang, F1
Daizumoto, K; Dondoo, TO; Fukawa, T; Fukumori, T; Kanayama, HO; Kohzuki, M; Kowada, M; Kusuhara, Y; Mori, H; Nakatsuji, H; Takahashi, M1
Appleman, L; Beumer, JH; Holleran, JL; Kim, KP; Lewis, LD; Morris, MJ; Parise, RA; van Erp, N1
Armstrong, CM; Cucchiara, V; Evans, CP; Gao, AC; Gu, X; Liu, C; Lombard, AP; Lou, W; Nadiminty, N; Pan, CX; Yang, JC1
Baron, B; Chowdhury, S; Hasabou, N; Heidenreich, A; Klotz, L; Lin, P; Shore, ND; Siemens, DR; van Os, S; Villers, A; Wang, F1
Anai, S; Fujimoto, K; Inoue, T; Miyake, M; Nakai, Y; Tanaka, N1
Akaev, I; Brennan, PA; Chhikara, R; Dabab, N; Fonseca, F; Gomez, RS; Rahimi, S; Rigby, E; Yeoh, CC1
Ferroni, C; Varchi, G1
Beijnen, JH; de Jong, KAM; de Vries, N; Rosing, H; van Nuland, M; Venekamp, N1
Adachi, T; Deguchi, T; Harimoto, K; Hase, T; Iguchi, T; Ishii, K; Iwamoto, K; Iwata, H; Kanamaru, T; Kato, M; Machida, Y; Morimoto, K; Nakatani, T; Ohmachi, T; Takegaki, Y; Tamada, S; Tashiro, K; Yamamoto, S; Yasuda, S1
Akamatsu, S; Fujimoto, Y; Inoue, T; Kimura, T; Kobayashi, T; Matsubara, N; Mori, K; Murakami, K; Ogawa, O; Terada, N1
Gu, Y; He, M; Peng, Y; Qu, F; Sun, J; Wang, G; Wang, Q; Zhou, F1
Grellety, T1
Fujita, K; Imamura, R; Kawashima, A; Kiuchi, H; Koh, Y; Miyagawa, Y; Nagahara, A; Nonomura, N; Uemura, M; Ujike, T1
Kolesar, JM; Momo, HD; Myint, ZW; Otto, DE; Wang, P; Yan, D1
Agarwal, N; Bilen, MA; Hahn, AW1
Cher, ML; Chinni, S; Dickow, B; Dobson, K; Fontana, JA; Heath, EI; Heilbrun, LK; Hwang, C; Jasti, P; Monk, P; Semaan, L; Smith, D; Sonpavde, G; Tejwani, S; Vaishampayan, UN1
Gim, HJ; Houk, KN; Jung, ME; Park, J1
Carpenter, V; Faber, AC; Gewirtz, DA; Harada, H; Min Lee, S; Murray, G; Reed, J; Saleh, T; Souers, A1
Agarwal, N; Armstrong, AJ; Concepcion, RS; Duggan, W; Dunshee, CJ; Haas, GP; Higano, CS; Karsh, LI; Olsson, CA; Penson, DF; Shen, Q; Sugg, J1
Ahlm, C; Allard, A; Angelin, M; Balkhed, ÅÖ; Becker, M; Bjartell, A; Bremell, D; Buckland, R; Carlsson, CT; Connolly, AF; Fonseca-Rodríguez, O; Freyhult, E; Gisslén, M; Henningsson, AJ; Josefsson, A; Lenman, A; Lindquist, E; Nilsson, AC; Niward, K; Överby, AK; Repo, J; Robinsson, D; Rosendal, E; Rudolfsson, S; Stranne, J; Styrke, J; Welén, K1
Cardoso, AM; Maia, CJ; Nascimento, D; Passarinha, L; Rocha, SM; Socorro, S1
Bi, J; Wang, J; Zhang, G; Zhang, X1

Reviews

6 review(s) available for bicalutamide and mdv 3100

ArticleYear
Therapeutic Strategies to Target the Androgen Receptor.
    Journal of medicinal chemistry, 2022, 07-14, Volume: 65, Issue:13

    Topics: Androgen Antagonists; Androgen Receptor Antagonists; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen

2022
Targeting the androgen receptor in prostate cancer.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:10

    Topics: Androgen Antagonists; Anilides; Antibodies, Neutralizing; Anticarcinogenic Agents; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Curcumin; Flutamide; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Male; Molecular Targeted Therapy; Nitriles; Oligonucleotides, Antisense; Phenylthiohydantoin; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Tosyl Compounds

2014
Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target.
    Current medicinal chemistry, 2019, Volume: 26, Issue:33

    Topics: Androgen Receptor Antagonists; Androstenes; Anilides; Benzamides; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds

2019
[Androgen receptor-positive triple negative breast cancer: From biology to therapy].
    Bulletin du cancer, 2020, Volume: 107, Issue:4

    Topics: Abiraterone Acetate; Age Factors; Aged; Androgen Antagonists; Anilides; Benzamides; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Female; Forecasting; Humans; Mutation; Nitriles; Phenylthiohydantoin; Prognosis; Rare Diseases; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Triple Negative Breast Neoplasms

2020
Evaluation of Fall and Fracture Risk Among Men With Prostate Cancer Treated With Androgen Receptor Inhibitors: A Systematic Review and Meta-analysis.
    JAMA network open, 2020, 11-02, Volume: 3, Issue:11

    Topics: Abiraterone Acetate; Accidental Falls; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Benzamides; Case-Control Studies; Fractures, Bone; Humans; Incidence; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Pyrazoles; Risk Factors; Thiohydantoins; Tosyl Compounds; Trauma Severity Indices

2020
The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Androgen Receptor Antagonists; Humans; Male; Network Meta-Analysis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Treatment Outcome

2023

Trials

10 trial(s) available for bicalutamide and mdv 3100

ArticleYear
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
    Science (New York, N.Y.), 2009, May-08, Volume: 324, Issue:5928

    Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Benzamides; Biological Availability; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; DNA; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Transcription, Genetic; Xenograft Model Antitumor Assays

2009
Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
    The Journal of biological chemistry, 2013, Jul-05, Volume: 288, Issue:27

    Topics: Androgen Receptor Antagonists; Androgens; Anilides; Animals; Benzamides; Cell Line, Tumor; Curcumin; Down-Regulation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Smad3 Protein; Tosyl Compounds; Transforming Growth Factor beta1; Transplantation, Heterologous; Xenograft Model Antitumor Assays

2013
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
    The Lancet. Oncology, 2016, Volume: 17, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia; Anilides; Arthralgia; Back Pain; Benzamides; Constipation; Disease Progression; Disease-Free Survival; Double-Blind Method; Dyspnea; Fatigue; Fractures, Spontaneous; Heart Failure; Hot Flashes; Humans; Hydronephrosis; Hypertension; Male; Middle Aged; Myocardial Infarction; Nausea; Nitriles; Patient Dropouts; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds

2016
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 06-20, Volume: 34, Issue:18

    Topics: Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Benzamides; Double-Blind Method; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds

2016
Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial.
    European urology, 2017, Volume: 71, Issue:4

    Topics: Anilides; Antineoplastic Agents; Benzamides; Cancer Pain; Carcinoma; Double-Blind Method; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Tosyl Compounds; Treatment Outcome

2017
Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.
    The Journal of urology, 2018, Volume: 199, Issue:1

    Topics: Age Factors; Aged; Anilides; Antineoplastic Agents; Benzamides; Double-Blind Method; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds; Treatment Outcome

2018
Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: the OCUU-CRPC study.
    International journal of clinical oncology, 2020, Volume: 25, Issue:3

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Flutamide; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds; Treatment Outcome

2020
Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
    JAMA network open, 2021, 01-04, Volume: 4, Issue:1

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Black or African American; Drug Therapy, Combination; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome

2021
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial.
    Prostate cancer and prostatic diseases, 2022, Volume: 25, Issue:2

    Topics: Androgen Antagonists; Anilides; Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Tosyl Compounds; Treatment Outcome

2022
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data.
    European urology, 2022, Volume: 81, Issue:3

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Anilides; Benzamides; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Female; Hospitalization; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Retrospective Studies; SARS-CoV-2; Sweden; Testosterone; Tosyl Compounds; Treatment Outcome

2022

Other Studies

49 other study(ies) available for bicalutamide and mdv 3100

ArticleYear
Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC).
    Journal of medicinal chemistry, 2010, Apr-08, Volume: 53, Issue:7

    Topics: Androgen Receptor Antagonists; Androgens; Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Male; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship; Thiohydantoins; Tumor Burden; Xenograft Model Antitumor Assays

2010
Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives.
    Journal of medicinal chemistry, 2013, Feb-14, Volume: 56, Issue:3

    Topics: Benzimidazoles; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Humans; Male; Molecular Structure; Prostate-Specific Antigen; Receptors, Androgen

2013
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
    Journal of medicinal chemistry, 2013, Jun-27, Volume: 56, Issue:12

    Topics: Androstadienes; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Design; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Proteolysis; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Transcriptional Activation

2013
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors.
    ACS chemical biology, 2013, Nov-15, Volume: 8, Issue:11

    Topics: Androgen Antagonists; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Delivery Systems; Histone Deacetylase Inhibitors; Humans; Inhibitory Concentration 50; Male; Microscopy, Confocal; Models, Biological; Prostatic Neoplasms; Receptors, Androgen

2013
Novel C-4 heteroaryl 13-cis-retinamide Mnk/AR degrading agents inhibit cell proliferation and migration and induce apoptosis in human breast and prostate cancer cells and suppress growth of MDA-MB-231 human breast and CWR22Rv1 human prostate tumor xenogra
    Journal of medicinal chemistry, 2015, Feb-26, Volume: 58, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Eukaryotic Initiation Factor-4E; Humans; Male; MCF-7 Cells; Mice; Mice, Nude; Mice, SCID; Molecular Structure; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Receptors, Adrenergic; Signal Transduction; Structure-Activity Relationship; Tretinoin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2015
Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists.
    European journal of medicinal chemistry, 2015, Jun-24, Volume: 99

    Topics: Androgen Receptor Antagonists; Animals; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Design; Humans; Imidazolidines; Male; Molecular Docking Simulation; Protein Conformation; Rats; Rats, Sprague-Dawley; Receptors, Androgen

2015
7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.
    Bioorganic & medicinal chemistry letters, 2016, Apr-15, Volume: 26, Issue:8

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Male; Models, Molecular; Molecular Structure; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship; Umbelliferones

2016
Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer.
    European journal of medicinal chemistry, 2016, Aug-08, Volume: 118

    Topics: Anilides; Antineoplastic Agents; Benzamides; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Design; Drug Resistance, Neoplasm; Humans; Male; Microsomes, Liver; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitriles; Permeability; Phenylthiohydantoin; Prostatic Neoplasms; Protein Conformation; Receptors, Androgen; Tosyl Compounds

2016
Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.
    Bioorganic & medicinal chemistry letters, 2016, 08-01, Volume: 26, Issue:15

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Male; Molecular Docking Simulation; Molecular Structure; Prostatic Neoplasms; Structure-Activity Relationship; Xylenes

2016
Identification of Triptophenolide from
    ACS medicinal chemistry letters, 2016, Dec-08, Volume: 7, Issue:12

    Topics:

2016
Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor.
    European journal of medicinal chemistry, 2018, Sep-05, Volume: 157

    Topics: Androgen Antagonists; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Genetic Variation; HEK293 Cells; Humans; Models, Molecular; Molecular Structure; Receptors, Androgen; Small Molecule Libraries; Structure-Activity Relationship

2018
A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
    European journal of medicinal chemistry, 2019, Oct-15, Volume: 180

    Topics: Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Ether-A-Go-Go Potassium Channels; Humans; Hydrocarbons, Fluorinated; Male; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Structure-Activity Relationship; Sulfhydryl Compounds; Tosyl Compounds

2019
Synthesis, biological evaluation and X-ray analysis of bicalutamide sulfoxide analogues for the potential treatment of prostate cancer.
    Bioorganic & medicinal chemistry letters, 2021, 03-15, Volume: 36

    Topics: Anilides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Male; Models, Molecular; Molecular Structure; Nitriles; Prostatic Neoplasms; Structure-Activity Relationship; Sulfoxides; Tosyl Compounds

2021
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.
    Journal of medicinal chemistry, 2021, 08-12, Volume: 64, Issue:15

    Topics: Amides; Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Male; Mice; Molecular Structure; Neoplasms, Experimental; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Receptors, Androgen; Structure-Activity Relationship

2021
Development of 2-(5,6,7-Trifluoro-1
    Journal of medicinal chemistry, 2021, 10-28, Volume: 64, Issue:20

    Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Development; Drug Screening Assays, Antitumor; Humans; Male; Models, Molecular; Molecular Structure; Prostatic Neoplasms, Castration-Resistant; Quinolines; Receptors, Androgen; Structure-Activity Relationship

2021
ARN-509: a novel antiandrogen for prostate cancer treatment.
    Cancer research, 2012, Mar-15, Volume: 72, Issue:6

    Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Benzamides; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Rats; Receptors, Androgen; Thiohydantoins; Tosyl Compounds; Xenograft Model Antitumor Assays

2012
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
    Cancer research, 2012, May-01, Volume: 72, Issue:9

    Topics: Androgen Receptor Antagonists; Androgens; Androstenes; Androstenols; Anilides; Benzamides; Binding, Competitive; Cell Line, Tumor; Drug Interactions; Eplerenone; Humans; Male; Metribolone; Nitriles; Phenylthiohydantoin; Prednisolone; Prostatic Neoplasms; Receptors, Androgen; Spironolactone; Tosyl Compounds

2012
FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide™).
    Molecular and cellular endocrinology, 2013, Jan-05, Volume: 365, Issue:1

    Topics: Anilides; Animals; Antineoplastic Agents, Hormonal; Benzamides; Cell Line, Tumor; Cell Nucleus; Chromatin Assembly and Disassembly; Female; HEK293 Cells; Hepatocyte Nuclear Factor 3-alpha; Humans; Male; Neoplasm Proteins; Nitriles; Nonsteroidal Anti-Androgens; Oocytes; Phenylthiohydantoin; Prostate; Prostatic Neoplasms; Protein Transport; Receptors, Androgen; Recombinant Proteins; RNA Interference; Tosyl Compounds; Xenopus laevis

2013
Complete biochemical (prostate-specific antigen) response to sipuleucel-T with enzalutamide in castration-resistant prostate cancer: a case report with implications for future research.
    Urology, 2013, Volume: 81, Issue:2

    Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Cancer Vaccines; Gonadotropin-Releasing Hormone; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Tissue Extracts; Tosyl Compounds; Treatment Outcome

2013
Bone morphogenetic protein-6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages.
    Cancer science, 2013, Volume: 104, Issue:8

    Topics: Androgen Receptor Antagonists; Androgens; Anilides; Animals; Benzamides; Benzofurans; Bone Morphogenetic Protein 6; Cell Line, Tumor; Dihydrotestosterone; Humans; Interleukin-6; Lymphocytes, Tumor-Infiltrating; Macrophages; Male; Mice; Nitriles; Phenylthiohydantoin; Promoter Regions, Genetic; Prostatic Neoplasms, Castration-Resistant; Quinolines; Receptors, Androgen; Tosyl Compounds; Up-Regulation

2013
Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
    Cell death & disease, 2013, Aug-08, Volume: 4

    Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Movement; Chemokine CCL3; Coculture Techniques; Curcumin; Humans; Macrophages; Male; Mice; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Signal Transduction; STAT3 Transcription Factor; Tosyl Compounds

2013
Surgical stress delays prostate involution in mice.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: Adrenergic beta-Antagonists; Androgen Antagonists; Androgens; Anilides; Animals; Apoptosis; bcl-Associated Death Protein; Benzamides; Gene Expression Regulation; Male; Mice; Mutation; Nitriles; Orchiectomy; Phenylthiohydantoin; Propanolamines; Prostate; Receptors, Adrenergic, beta-2; Signal Transduction; Stress, Physiological; Tosyl Compounds

2013
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.
    Breast cancer research : BCR, 2014, Jan-22, Volume: 16, Issue:1

    Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Benzamides; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Estrogen Receptor alpha; Female; Humans; MCF-7 Cells; Mice; Middle Aged; Neoplasm Transplantation; Nitriles; Phenylthiohydantoin; Receptors, Androgen; Signal Transduction; Tamoxifen; Tosyl Compounds; Transplantation, Heterologous

2014
Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.
    Molecular and cellular endocrinology, 2014, Apr-25, Volume: 387, Issue:1-2

    Topics: Aged; Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Evaluation, Preclinical; Female; Humans; Isoxazoles; Male; Mice; Mice, Inbred DBA; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Progesterone; Tosyl Compounds; Xenograft Model Antitumor Assays

2014
Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:3

    Topics: Androgen Antagonists; Androgens; Anilides; Benzamides; Cell Line, Tumor; Cell Survival; Flutamide; Gene Expression Regulation, Neoplastic; Humans; Ligands; Male; Nitriles; Phenylthiohydantoin; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Proteasome Endopeptidase Complex; Receptors, Androgen; Signal Transduction; STAT5 Transcription Factor; Tosyl Compounds; Tumor Suppressor Proteins

2015
Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.
    Oncotarget, 2015, Jun-20, Volume: 6, Issue:17

    Topics: Androgen Antagonists; Anilides; Animals; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Endosomal Sorting Complexes Required for Transport; Humans; Immunohistochemistry; Male; Membrane Proteins; Mice, Nude; Nedd4 Ubiquitin Protein Ligases; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; RNA Interference; Tosyl Compounds; Transplantation, Heterologous; Tumor Burden; Ubiquitin-Protein Ligases

2015
Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
    Oncotarget, 2015, Jun-10, Volume: 6, Issue:16

    Topics: Anilides; Animals; Benzamides; Cell Line, Tumor; Heterografts; Humans; Male; MAP Kinase Signaling System; Mast Cells; Matrix Metalloproteinase 9; Mice; Neoplasm Invasiveness; Neoplastic Stem Cells; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Long Noncoding; Tosyl Compounds

2015
Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Sep-15, Volume: 21, Issue:18

    Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Androgen Antagonists; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Benzamides; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Rhodamines; Taxoids; Tosyl Compounds; Xenograft Model Antitumor Assays

2015
Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.
    Oncotarget, 2015, Sep-22, Volume: 6, Issue:28

    Topics: Androgen Antagonists; Anilides; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Immediate-Early Proteins; Male; Molecular Targeted Therapy; Mutation; Nitriles; Oligonucleotide Array Sequence Analysis; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Serine-Threonine Kinases; Receptors, Androgen; RNA Interference; Tosyl Compounds; Xenograft Model Antitumor Assays

2015
FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer.
    Oncotarget, 2015, Oct-06, Volume: 6, Issue:30

    Topics: Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 3-alpha; Humans; Kallikreins; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tosyl Compounds

2015
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
    Genome biology, 2016, Jan-26, Volume: 17

    Topics: Androgen Receptor Antagonists; Anilides; Benzamides; DNA; Drug Resistance, Neoplasm; Flutamide; High-Throughput Nucleotide Sequencing; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Tosyl Compounds

2016
ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Cancer letters, 2016, 07-01, Volume: 376, Issue:2

    Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Benzamides; Cell Line, Tumor; Cell Movement; Curcumin; Enhancer of Zeste Homolog 2 Protein; Humans; Male; Mice, Nude; Neoplasm Invasiveness; Neoplastic Stem Cells; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Side-Population Cells; Signal Transduction; STAT3 Transcription Factor; Tosyl Compounds; Xenograft Model Antitumor Assays

2016
The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators.
    The Journal of steroid biochemistry and molecular biology, 2017, Volume: 166

    Topics: Androgen Antagonists; Androgens; Androstadienes; Androstenes; Anilides; Animals; Benzamides; Benzimidazoles; Biological Assay; Cell Line; Cricetinae; Dihydrotestosterone; Flutamide; HEK293 Cells; Humans; Male; Microscopy, Fluorescence; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Transcription Factors; Two-Hybrid System Techniques

2017
Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
    Urologic oncology, 2016, Volume: 34, Issue:10

    Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dihydrotestosterone; Down-Regulation; Flutamide; Humans; Interleukin-6; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Nitriles; Phenylthiohydantoin; Receptors, Androgen; RNA; Tosyl Compounds; Transcription, Genetic; Urinary Bladder Neoplasms

2016
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide.
    Oncotarget, 2016, Sep-13, Volume: 7, Issue:37

    Topics: Androstenes; Anilides; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mutation; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tosyl Compounds

2016
Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Anticancer research, 2017, Volume: 37, Issue:1

    Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents, Hormonal; Benzamides; Blood Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Galectin 3; Galectins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Nitriles; Oligonucleotide Array Sequence Analysis; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Real-Time Polymerase Chain Reaction; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Transcription, Genetic; Xenograft Model Antitumor Assays

2017
Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS.
    Journal of pharmaceutical and biomedical analysis, 2017, May-10, Volume: 138

    Topics: Androstenes; Anilides; Benzamides; Chromatography, Liquid; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Spectrometry, Mass, Electrospray Ionization; Tosyl Compounds

2017
Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
    Molecular cancer therapeutics, 2017, Volume: 16, Issue:8

    Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Male; Mice; Niclosamide; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds

2017
Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide.
    BMC research notes, 2018, May-29, Volume: 11, Issue:1

    Topics: Aged; Aged, 80 and over; Androstenes; Anilides; Antineoplastic Agents; Benzamides; Disease-Free Survival; Flutamide; Humans; Male; Middle Aged; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tosyl Compounds

2018
Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2018, Volume: 47, Issue:7

    Topics: Adenocarcinoma; Administration, Oral; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Female; Humans; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Tosyl Compounds

2018
Development and validation of an UPLC-MS/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2019, Feb-01, Volume: 1106-1107

    Topics: Administration, Oral; Anastrozole; Androstadienes; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Benzamides; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Nitriles; Phenylthiohydantoin; Tamoxifen; Tandem Mass Spectrometry; Tosyl Compounds

2019
Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
    Clinical genitourinary cancer, 2020, Volume: 18, Issue:1

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Flutamide; Follow-Up Studies; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Tosyl Compounds

2020
Metabolomic profiling to evaluate the efficacy of proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells.
    Investigational new drugs, 2020, Volume: 38, Issue:5

    Topics: Amino Acids; Androgen Receptor Antagonists; Anilides; Benzamides; Cell Line, Tumor; Cell Survival; Glutathione; Humans; Male; Metabolome; Metabolomics; Nitriles; Nucleosides; Oxazoles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Thiohydantoins; Tosyl Compounds

2020
Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
    Anti-cancer drugs, 2020, Volume: 31, Issue:10

    Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kallikreins; Leuprolide; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Testosterone; Tosyl Compounds

2020
Successful Recruitment of Black Men to Prostate Cancer Clinical Trials-A Lesson in Achievement.
    JAMA network open, 2021, 01-04, Volume: 4, Issue:1

    Topics: Androgen Antagonists; Androgens; Anilides; Benzamides; Black or African American; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome

2021
Conformational dynamics of androgen receptors bound to agonists and antagonists.
    Scientific reports, 2021, 08-05, Volume: 11, Issue:1

    Topics: Androgen Receptor Antagonists; Androgens; Anilides; Benzamides; Binding Sites; Dihydrotestosterone; Humans; Imidazoles; Ligands; Molecular Conformation; Molecular Dynamics Simulation; Nitriles; Phenylthiohydantoin; Principal Component Analysis; Protein Binding; Protein Conformation; Receptors, Androgen; Thiohydantoins; Tosyl Compounds

2021
Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
    Biochemical pharmacology, 2021, Volume: 193

    Topics: Anilides; Aniline Compounds; Animals; Antineoplastic Agents; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; Cellular Senescence; Docetaxel; Humans; Male; Mice; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sulfonamides; Tosyl Compounds; Xenograft Model Antitumor Assays

2021
STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide.
    Molecular medicine reports, 2023, Volume: 27, Issue:2

    Topics: Androgen Antagonists; Antigens, Neoplasm; Humans; Male; Nitriles; Oxidoreductases; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant

2023